Tech Transfer Roundup: Inside Merck’s Approach To Academic Partnering

Merck & Co. Inc.’s Kim Folander believes collaboration between big pharma and academic or institutional researchers may take on an increasingly important role in pipeline expansion as the competition for later-stage in-licensing assets grows stronger.

“From the larger industry perspective, it’s harder and harder to find late-stage therapeutics of any kind,” Folander, Merck’s executive director of licensing and enabling technology, said in an interview. “They...